AzTrials
AzTrials

ArthritisPhase 3NCT00733902

Tanezumab in Osteoarthritis of the Knee

A Phase 3 study testing tanezumab in people with Arthritis and Osteoarthritis, run by Pfizer at 82 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Arthritis, Osteoarthritis
What is being tested?
tanezumab
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
697 participants
Where
82 sitesUnited States
Study dates
15 Sep 2008to 14 Jan 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Osteoarthritis of the knee according to ACR criteria with a Kellgren-Lawrence x-ray grade of 2.
  • Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery.
  • Pain level and function levels as required by the protocol at Screening and Baseline.
  • Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study.
  • Must agree to the contraceptive requirements of the protocol if applicable.
  • Must agree to the treatment plan, scheduled visits, and procedures of the protocol.

Who cannot join

  • Pregnancy or intent to become pregnant during the study
  • BMI greater than 39
  • other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

Trial locations and contacts

82 sites in 1 country.

82 sites in 1 country

United States82 sites
  • Albuquerque Clinical Trials, Inc.

    Albuquerque, New Mexico, 87102

  • New Mexico Clinical Research & Osteoporosis Center, Incorporated

    Albuquerque, New Mexico, 87106

  • Ann Arbor Clinical Research

    Ann Arbor, Michigan, 48103

  • Laureate Clinical Reseach Group

    Atlanta, Georgia, 30342

  • Maine Research Associates

    Auburn, Maine, 04210

  • Walter Chase, MD

    Austin, Texas, 78705

  • Office of Peter A. Holt, MD

    Baltimore, Maryland, 21239

  • Gulf Coast Research, LLC

    Baton Rouge, Louisiana, 70808

  • The Baton Rouge Clinic

    Baton Rouge, Louisiana, 70808

  • EPIC Imaging West

    Beaverton, Oregon, 97008

  • Comprehensive Clinical Research

    Berlin, New Jersey, 08009

  • East Penn Rheumatology Associates, PC

    Bethlehem, Pennsylvania, 18015

  • Sonora Clinical Research

    Boise, Idaho, 83702

  • Arthristis and Osteoporosis Consultants of the Carolinas

    Charlotte, North Carolina, 28207-1198

  • Charlottesville Medical Research

    Charlottesville, Virginia, 22911

  • Hilltop Physicians Inc, Hightop Medical Research Center

    Cincinnati, Ohio, 45224

  • Innovative Research of West Florida, Inc.

    Clearwater, Florida, 33756

  • Tampa Bay Medical Research, Inc.

    Clearwater, Florida, 33761

  • Metroplex Clinical Research Center

    Dallas, Texas, 75231

  • Clinical Research Center of Connecticut

    Danbury, Connecticut, 06810

  • Jefrey D. Lieberman, MD, PC

    Decatur, Georgia, 30033

  • Avail Clinical Rearch, LLC

    DeLand, Florida, 32720

  • Avail Clinical Research

    DeLand, Florida, 32720

  • Arthritis Associates of South Florida, Clinical Research Center

    Delray Beach, Florida, 33484

  • Delray Research Associates

    Delray Beach, Florida, 33484

  • Brandywine Clinical Research

    Downingtown, Pennsylvania, 19335-2620

  • Altoona Center for Clinical Research

    Duncansville, Pennsylvania, 16635-0909

  • MAPS Applied Research Center

    Edina, Minnesota, 55435

  • Medical Advanced Pain Specialists

    Edina, Minnesota, 55435

  • Health Sciences Research Center at Asthma & Allergy Assoc., PC

    Elmira, New York, 14901

  • Early Family Practice Center

    Fort Valley, Georgia, 31030

  • The Arthritis and Osteoporosis Center of Maryland

    Frederick, Maryland, 21702

  • Pharmquest

    Greensboro, North Carolina, 27408

  • Health Sciences Research Center at Asthma and Allergy Associates P.C.

    Ithaca, New York, 14850

  • Westside Center for Clinical Research

    Jacksonville, Florida, 32205

  • Appalachian Medical Research

    Johnson City, Tennessee, 37604-1417

  • Clinical Research Consortium

    Las Vegas, Nevada, 89119

  • Arthritis Center of Lexington

    Lexington, Kentucky, 40504

  • Bluegrass Community Research, Inc

    Lexington, Kentucky, 40515

  • David H. Neustadt P.S.C.

    Louisville, Kentucky, 40202

  • Mansfield Health Center

    Mansfield, Massachusetts, 02048

  • North Georgia Clinical Research

    Marietta, Georgia, 30060

  • Neurorehabilitation & Diagnostic Services

    Miami, Florida, 33126

  • Pharmax Research Clinic, LLC

    Miami, Florida, 33126

  • South Medical Research Group

    Miami, Florida, 33186

  • Southwest Rheumatology and Research Group, LLC

    Middleburg Heights, Ohio, 44130

  • Arthritis and Diabetes Clinic

    Monroe, Louisiana, 71203

  • The Medical Research Network, LLC

    New York, New York, 10128

  • Javed Rheumatology Associates, Inc.

    Newark, Delaware, 19713

  • Health Research Institute

    Oklahoma City, Oklahoma, 73109

  • Compass Research, LLC

    Orlando, Florida, 32806

  • The Arthritis Center

    Palm Harbor, Florida, 34684

  • Arthritis Associates Inc.

    Peabody, Massachusetts, 01960-1628

  • University Clinical Research Incorporated

    Pembroke Pines, Florida, 33024

  • Arizona Research Center, Inc.

    Phoenix, Arizona, 85023

  • Advent Clinical Research Centers

    Pinellas Park, Florida, 33781

  • Prem C. Chatpar, MD, LLC

    Plainview, New York, 11803

  • AVIVOCLIN Clinical Services

    Port Orange, Florida, 32127

  • EPIC Imaging East:

    Portland, Oregon, 97220

  • Covance CRU, Inc.

    Portland, Oregon, 97239

  • C.A.R.E. Center

    Raleigh, North Carolina, 27609

  • Health Concepts

    Rapid City, South Dakota, 57702

  • AAIR Research Center

    Rochester, New York, 14618

  • KMED Research

    Saint Clair Shores, Michigan, 48081

  • Radiant Research

    San Antonio, Texas, 78217

  • Texas Arthritis Research Center, PA

    San Antonio, Texas, 78217

  • Diagnostics Research Group

    San Antonio, Texas, 78229

  • Memorial Health System, Inc./ Michiana Arthritis & Osteoporosis Center

    South Bend, Indiana, 46601-1071

  • Memorial Health System, Inc.

    South Bend, Indiana, 46601

  • The Arthritis Center

    Springfield, Illinois, 62704

  • Mercy Health Research

    St Louis, Missouri, 63141

  • Dale G. Bramlet, MD, P.L

    St. Petersburg, Florida, 33713

  • Stamford Therapeutics Consortium

    Stamford, Connecticut, 06905

  • Northwest Indiana Center for Clinical Research

    Valparaiso, Indiana, 46383

  • Palm Beach Research Center

    West Palm Beach, Florida, 33409

  • The Center for Rheumatology and Bone Research

    Wheaton, Maryland, 20902

  • Piedmont Medical Research Associates

    Winston-Salem, North Carolina, 27103

  • North Georgia Clinical Research

    Woodstock, Georgia, 30189

  • North Georgia Internal Medicine

    Woodstock, Georgia, 30189

  • Clinical Pharmacology Study Group

    Worcester, Massachusetts, 01610

  • Clinical Trials Northwest

    Yakima, Washington, 98902

  • Pharmacotherapy Research Associates,Inc

    Zanesville, Ohio, 43701

Other trials in United States

About this study

Official title: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE

Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients.

Being tested
tanezumab, Placebo
Keywords
monoclonal antibody, RN624, PF-04383119, nerve growth factor, anti-nerve growth factor, OA, pain
Medical subject headings
Arthritis, Osteoarthritis, Hereditary Sensory and Autonomic Neuropathies, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • tanezumabBiological

    IV tanezumab 10 mg at 1 dose every 8 weeks

  • tanezumabBiological

    IV tanezumab 5 mg at 1 dose every 8 weeks

  • tanezumabBiological

    IV tanezumab 2.5 mg at 1 dose every 8 weeks

  • PlaceboBiological

    IV placebo to match tanezumab at 1 dose every 8 weeks

Study groups in NCT00733902
Study groupRoleWhat they receive
Tanezumab 10 mgExperimentalNot described
Receives: Biological: tanezumab
Tanezumab 5 mgExperimentalNot described
Receives: Biological: tanezumab
Tanezumab 2.5 mgExperimentalNot described
Receives: Biological: tanezumab
PlaceboPlacebo comparatorNot described
Receives: Biological: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.

    Measured: Baseline (Day 1), Week 16

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 16: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.

    Measured: Baseline, Week 16

  3. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 16: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today?". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

    Measured: Baseline, Week 16

Secondary outcomes (25)
  1. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 24

  2. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  3. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living

    Measured: Baseline, Week 2, 4, 8, 12, 24

  4. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index joint during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  5. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscales at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  6. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  7. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 24: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

    Measured: Baseline, Week 2, 4, 8, 12, 24

  8. Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis at Week 2, 4, 8, 12, 16, 24: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  9. Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)

    OMERACT-OARSI response: greater than or equal to (>=) 50 percent (%) improvement from baseline and absolute change from baseline of >=2 units at Week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at Week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).

    Measured: Week 2, 4, 8, 12, 16, 24

  10. Percentage of Participants With Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)

    OMERACT-OARSI response: >= 50% improvement from baseline and absolute change from baseline of >=2 units at Week of interest in WOMAC pain or physical function subscale, or at least 2 of the following 3 being true: >=20% improvement from baseline and absolute change from baseline of >=1 unit at Week of interest in 1) WOMAC pain subscale, 2) WOMAC physical function subscale, 3) PGA of osteoarthritis (score: 1-5, higher score=more affected). WOMAC pain, physical function subscales assess amount of pain/difficulty experienced (score: 0-10, higher score=higher pain/difficulty).

    Measured: Week 2, 4, 8, 12, 16, 24

  11. Percentage of Participants With at Least 30% and 50% Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  12. Percentage of Participants With at Least 30 Percent (%) and 50% Reduction From Baseline in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  13. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Baseline Observation Carried Forward (BOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  14. Percentage of Participants With at Least 2 Points Improvement From Baseline in Patient Global Assessment (PGA) of Osteoarthritis: Last Observation Carried Forward (LOCF)

    Participants answered: "Considering all the ways your osteoarthritis in your knee affects you, how are you doing today". Participants responded on a scale ranging from 1-5, where 1= very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  15. Percentage of Participants With Cumulative Reduction From Baseline to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline up to Week 16 are reported.

    Measured: Baseline up to Week 16

  16. Percentage of Participants With Cumulative Reduction From Baseline to Week 16 in Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)

    WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 to 10, where higher scores indicate higher pain. Participants with specified reduction (as percent) from baseline up to Week 16 are reported.

    Measured: Baseline up to Week 16

  17. Change From Baseline in Average Pain Score in the Index Knee at Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24: Baseline Observation Carried Forward (BOCF)

    Participants assessed daily average knee pain during the past 24 hours on an 11-point NRS ranging from 0 (no pain) to 10 (worst pain). Baseline score was calculated as the mean of the scores over the 3 days and a weekly mean was calculated using the daily pain scores within each study week. The change from Baseline was calculated using difference between each post-baseline weekly mean and the Baseline mean score.

    Measured: Baseline, Week 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24

  18. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF)

    WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items) and physical function (17 items) in participants with osteoarthritis of knee. WOMAC average score is the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher score indicates worse response.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  19. Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item at Week 2, 4, 8, 12, 16, 24: Baseline Observation Carried Forward (BOCF)

    Participants answered, Question (Q)1: "How much pain have you had when walking on a flat surface?" and Q2: "How much pain have you had when going up or down the stairs?". Participants responded by using a NRS of 0 to 10, where 0 = no pain and 10 = extreme pain.

    Measured: Baseline, Week 2, 4, 8, 12, 16, 24

  20. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12, 24: Baseline Observation Carried Forward (BOCF)

    SF-36v2: standardized survey evaluating 8 domains of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each domain were scaled 0 (poor health) to 100 (best health), higher scores indicating good health condition.

    Measured: Baseline, Week 12, 24

  21. Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12, 24: Baseline Observation Carried Forward (BOCF)

    SF-36v2: standardized survey evaluating 8 domains of functional health and wellbeing (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health). Total score for each domain were scaled 0 (poor health) to 100 (best health), higher scores indicating good health condition. For obtaining physical and mental component scores, z-score for each scale = (observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.

    Measured: Baseline, Week 12, 24

  22. Time to Discontinuation Due to Lack of Efficacy

    Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.

    Measured: Baseline up to Week 16

  23. Percentage of Participants Who Used Rescue Medications

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.

    Measured: Week 2, 4, 8, 12, 16, 24

  24. Duration of Rescue Medication Use

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.

    Measured: Week 2, 4, 8, 12, 16, 24

  25. Amount of Rescue Medication Taken

    In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days per week could be taken as rescue medication.

    Measured: Week 2, 4, 8, 12, 16, 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Aug 2008 (estimated)
  2. Study start15 Sep 2008
  3. Primary completion24 Aug 2009
  4. Study completion14 Jan 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
697 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00733902
Sponsor's protocol ID
A4091011
Other IDs
P3 OA KNEE
Status last verified
Feb 2021
First submitted
11 Aug 2008
Last updated
22 Mar 2021
Data monitoring committee
Yes
Individual data sharing
Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.

Publications

  • Brown MT, Cornblath DR, Koltzenburg M, Gorson KC, Hickman A, Pixton GC, Gaitonde P, Viktrup L, West CR. Peripheral Nerve Safety of Nerve Growth Factor Inhibition by Tanezumab: Pooled Analyses of Phase III Clinical Studies in Over 5000 Patients with Osteoarthritis. Clin Drug Investig. 2023 Jul;43(7):551-563. doi: 10.1007/s40261-023-01286-3. Epub 2023 Jul 18.

    PubMed 37460782
  • Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.

    PubMed 30936738
  • Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.

    PubMed 26554876

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing tanezumab in people with Arthritis and Osteoarthritis, run by Pfizer at 82 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 82 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 22 Mar 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 16: Baseline Observation Carried Forward (BOCF) (time frame: Baseline (Day 1), Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00733902, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in